Literature DB >> 8549238

Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature.

H M Brink1, L V Beex.   

Abstract

Ocular side effects of systemic fluorouracil include excessive lacrimation, due to punctal and canalicular stenosis and fibrosis. Obstruction of the tear ducts after systemic therapy with fluorouracil is more frequent than is assumed. Five patients with breast cancer and punctal or canalicular stenosis are presented. Although complaints of epiphora usually resolve two weeks after cessation of systemic therapy, local antibiotics and steroids may be indicated. In patients with persisting complaints, and patients treated with fluorouracil for a prolonged period of time, prophylactic intubation of the tear ducts with silastic tubes has been advocated. (Conjunctivo)dacryocystorhinostomy may be unavoidable.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8549238     DOI: 10.1007/bf01203288

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  22 in total

1.  An evaluation of 5-fluorouracil in malignant disease.

Authors:  A J WEISS; L G JACKSON; R CARABASI
Journal:  Ann Intern Med       Date:  1961-11       Impact factor: 25.391

Review 2.  Neurotoxicity of commonly used antineoplastic agents (first of two parts).

Authors:  H D Weiss; M D Walker; P H Wiernik
Journal:  N Engl J Med       Date:  1974-07-11       Impact factor: 91.245

3.  Excessive lacrimation from fluorouracil treatment.

Authors:  J Hamersley; J K Luce; T R Florentz; M M Burkholder; J J Pepper
Journal:  JAMA       Date:  1973-08-13       Impact factor: 56.272

4.  Tear-duct fibrosis (dacryostenosis) due to 5-fluorouracil.

Authors:  D J Haidak; B S Hurwitz; K Y Yeung
Journal:  Ann Intern Med       Date:  1978-05       Impact factor: 25.391

Review 5.  Eye toxicity of cancer chemotherapy: a review of the literature.

Authors:  J D Griffin; M B Garnick
Journal:  Cancer       Date:  1981-10-01       Impact factor: 6.860

6.  Ankyloblepharon associated with systemic 5-fluorouracil treatment.

Authors:  M S Insler; C J Helm
Journal:  Ann Ophthalmol       Date:  1987-10

Review 7.  Ocular complications of systemic cancer chemotherapy.

Authors:  P S Imperia; H M Lazarus; J H Lass
Journal:  Surv Ophthalmol       Date:  1989 Nov-Dec       Impact factor: 6.048

8.  Surgical treatment of punctal-canalicular fibrosis from 5-fluorouracil therapy.

Authors:  S R Seiff; N Shorr; T Adams
Journal:  Cancer       Date:  1985-10-15       Impact factor: 6.860

9.  Punctal-canalicular stenosis related to systemic fluorouracil therapy.

Authors:  L P Caravella; J A Burns; M Zangmeister
Journal:  Arch Ophthalmol       Date:  1981-02

10.  Fluorouracil Filtering Surgery Study one-year follow-up. The Fluorouracil Filtering Surgery Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1989-12-15       Impact factor: 5.258

View more
  13 in total

1.  Clinical features and treatment outcomes of patients with tearing after chemotherapy.

Authors:  Jinhwan Park; Joohyun Kim; Sehyun Baek
Journal:  Eye (Lond)       Date:  2018-12-10       Impact factor: 3.775

2.  Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.

Authors:  R B Raffa; R J Tallarida
Journal:  J Clin Pharm Ther       Date:  2010-06       Impact factor: 2.512

3.  Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug.

Authors:  Tsugihisa Sasaki; Hiroaki Miyashita; Tamon Miyanaga; Katsushi Yamamoto; Kazuhisa Sugiyama
Journal:  Jpn J Ophthalmol       Date:  2012-03-13       Impact factor: 2.447

4.  Epiphora as a side effect of topical mitomycin C.

Authors:  E Dafgård Kopp; S Seregard
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

Review 5.  Supportive cryotherapy: a review from head to toe.

Authors:  Kunal C Kadakia; Shaina A Rozell; Anish A Butala; Charles L Loprinzi
Journal:  J Pain Symptom Manage       Date:  2013-11-07       Impact factor: 3.612

6.  Predictive factors for ocular complications caused by anticancer drug S-1.

Authors:  Rika Yamada; Chie Sotozono; Takahiro Nakamura; Akihiro Nishida; Shinya Nakanishi; Masaki Hirabatake; Akihito Tsuji; Yasuo Kurimoto
Journal:  Jpn J Ophthalmol       Date:  2016-02-03       Impact factor: 2.447

7.  Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) regimen.

Authors:  A Karamitsos; V Kokkas; A Goulas; P Paraskevopoulos; K Gougoulias; V Karampatakis; K Boboridis
Journal:  Hippokratia       Date:  2013-04       Impact factor: 0.471

Review 8.  Breast cancer medications and vision: effects of treatments for early-stage disease.

Authors:  Alvin Eisner; Shiuh-Wen Luoh
Journal:  Curr Eye Res       Date:  2011-08-05       Impact factor: 2.424

9.  Noninvasive direct detection of ocular mucositis by in vivo confocal microscopy in patients treated with S-1.

Authors:  Tai-ichiro Chikama; Norihisa Takahashi; Makiko Wakuta; Teruo Nishida
Journal:  Mol Vis       Date:  2009-12-26       Impact factor: 2.367

10.  Punctal stenosis: definition, diagnosis, and treatment.

Authors:  Uri Soiberman; Hirohiko Kakizaki; Dinesh Selva; Igal Leibovitch
Journal:  Clin Ophthalmol       Date:  2012-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.